Gene: MAP4

4134
-
microtubule associated protein 4
protein-coding
3p21.31
Ensembl:ENSG00000047849 MIM:157132 Vega:OTTHUMG00000156828 UniprotKB:P27816
NG_052840.1
PubMed|SNP Mapped
1   ANCO-SNPs
OD|ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.637e-1 (AD)  2.636e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs34675858chr3:47860757 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CRTAP0.925
WNK10.923
PTP4A20.921
ANKRD400.916
CENPB0.909
FBXW40.909
CASC30.907
ZNF6640.907
NUDT160.902
MAP4K40.902

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.658
OR4F5-0.573
CUX2-0.264
HCN4-0.254
PRSS12-0.252
TPBG-0.247
PCDH8-0.247
FFAR4-0.247
NOS2-0.242
ASB2-0.241

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB01229PaclitaxelSmall Molecule33069-62-4ApprovedTarget
DB01248DocetaxelSmall Molecule114977-28-5Approved|InvestigationalTarget
DB11638ArtenimolSmall Molecule71939-50-9Approved|InvestigationalTarget
ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of MAP4 mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of MAP4 mRNA29067470
D000082AcetaminophenAcetaminophen affects the expression of MAP4 mRNA17562736
D020106AcrylamideAcrylamide results in increased expression of MAP4 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MAP4 gene27153756
D000452AldrinAldrin results in increased expression of MAP4 mRNA18579281
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of MAP4 mRNA24449571
D001151ArsenicArsenic affects the methylation of MAP4 gene25304211
D001554BenzeneBenzene results in decreased expression of MAP4 mRNA15929907
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MAP4 mRNA20064835
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MAP4 mRNA19770486|2222880
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MAP4 mRNA"26238291
C006780bisphenol Abisphenol A affects the expression of MAP4 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of MAP4 gene28505145
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP4 mRNA28628672
C013418bromfenacoumbromfenacoum results in decreased expression of MAP4 protein28903499
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of MAP4 mRNA15336504
D002104CadmiumCadmium results in increased expression of MAP4 mRNA24376830
C018021cobaltous chloridecobaltous chloride results in decreased expression of MAP4 mRNA19320972
D003300CopperCopper results in decreased expression of MAP4 mRNA16246896
C030973cupric oxidecupric oxide results in increased phosphorylation of MAP4 protein25470785
D016572CyclosporineCyclosporine results in increased expression of MAP4 mRNA20106945
D016572CyclosporineCyclosporine results in decreased expression of MAP4 mRNA19770486
C007262deoxynivalenoldeoxynivalenol results in decreased phosphorylation of MAP4 protein23811945
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP4 mRNA28628672
D003907DexamethasoneDexamethasone results in increased expression of MAP4 mRNA17998272
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of MAP4 mRNA21266533
D002945CisplatinCisplatin results in decreased expression of MAP4 mRNA27594783
D002945CisplatinCisplatin results in decreased phosphorylation of MAP4 protein22006019
C000944dicrotophosdicrotophos results in increased expression of MAP4 mRNA28302478
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of MAP4 mRNA17854601
D004052DiethylnitrosamineRB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of MAP4 mRNA]17854601
C039060dihydroartemisinindihydroartemisinin analog binds to MAP4 protein modified form26340163
D004317DoxorubicinDoxorubicin affects the expression of MAP4 protein12006519|2938556
D004317DoxorubicinDoxorubicin results in decreased expression of MAP4 protein12006519
D004791Enzyme Inhibitors[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of MAP4 protein23301498
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of MAP4 mRNA17555576
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of MAP4 mRNA17942748
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MAP4 mRNA17942748
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of MAP4 mRNA23649840
D005557FormaldehydeFormaldehyde results in decreased expression of MAP4 mRNA23649840
D019833GenisteinESR1 promotes the reaction [Genistein results in decreased expression of MAP4 protein]20884965
D019833GenisteinESR2 promotes the reaction [Genistein results in decreased expression of MAP4 protein]20884965
D019833GenisteinGenistein results in decreased expression of MAP4 mRNA16705744
D019833GenisteinGenistein results in decreased expression of MAP4 protein20884965
D005947Glucose[INS protein co-treated with Glucose] results in increased expression of MAP4 mRNA22634610
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP4 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP4 mRNA28628672
D007657Ketone BodiesKetone Bodies results in increased expression of MAP4 mRNA16807920
D007854LeadLead affects the splicing of MAP4 mRNA28903495
C042720mercuric bromidemercuric bromide results in increased expression of MAP4 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA"27188386
D008694MethamphetamineMethamphetamine results in increased expression of MAP4 mRNA26307267
C004925methylmercuric chloridemethylmercuric chloride affects the expression of MAP4 protein27012723
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of MAP4 mRNA23103053
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of MAP4 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MAP4 mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of MAP4 mRNA"20188158
C406082monomethylarsonous acidmonomethylarsonous acid results in decreased expression of MAP4 protein24625837
D009151Mustard GasMustard Gas results in decreased expression of MAP4 mRNA15674843
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of MAP4 mRNA"25620056
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of MAP4 mRNA25729387
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of MAP4 mRNA26272509
D010758PhosphorusPhosphorus results in increased expression of MAP4 mRNA17715259
C006253pirinixic acidpirinixic acid results in decreased expression of MAP4 mRNA17426115
C006253pirinixic acidpirinixic acid results in increased expression of MAP4 mRNA23811191
D011192Potassium DichromatePotassium Dichromate results in decreased expression of MAP4 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of MAP4 mRNA24780913
D011748PyrogallolPyrogallol results in increased expression of MAP4 mRNA20362636
C059514resveratrolresveratrol results in decreased expression of MAP4 mRNA12569576
C059514resveratrolresveratrol results in decreased expression of MAP4 protein18089832
D015474IsotretinoinIsotretinoin results in increased expression of MAP4 mRNA20436886
D012643SeleniumSelenium results in increased expression of MAP4 mRNA19244175
D012822Silicon DioxideSilicon Dioxide results in decreased expression of MAP4 mRNA22431001
D013096SpermineSpermine results in increased expression of MAP4 mRNA18673383
D013629TamoxifenTamoxifen affects the expression of MAP4 mRNA17555576
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MAP4 mRNA21570461
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MAP4 mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MAP4 mRNA21215274
D019284ThapsigarginThapsigargin results in increased expression of MAP4 protein24648495
D013849ThimerosalThimerosal results in decreased expression of MAP4 mRNA27188386
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of MAP4 mRNA25729387
C483909torcetrapibtorcetrapib results in increased expression of MAP4 mRNA23228038
D014241TrichloroethyleneTrichloroethylene results in decreased expression of MAP4 mRNA19448997
C057693troglitazonetroglitazone results in increased expression of MAP4 mRNA19140230
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MAP4 mRNA23179753|2597931
D014635Valproic AcidValproic Acid results in decreased expression of MAP4 mRNA26272509|2800136
D014635Valproic AcidValproic Acid affects the expression of MAP4 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of MAP4 gene25560391
D014748Vinca AlkaloidsMAP4 protein affects the susceptibility to Vinca Alkaloids12006519
C025643vinclozolinvinclozolin affects the expression of MAP4 mRNA19015723|2303416
C029297vinylidene chloridevinylidene chloride results in increased expression of MAP4 mRNA26682919
D014810Vitamin EVitamin E results in increased expression of MAP4 mRNA19244175
D024483Vitamin K 3Vitamin K 3 affects the expression of MAP4 mRNA20044591
C111237vorinostatvorinostat results in decreased expression of MAP4 mRNA27188386
D015032ZincZinc deficiency results in increased expression of MAP4 mRNA12888634

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-HDA22658674  22681889  
GO:0005198structural molecule activity-TAS1905296  
GO:0005515protein binding-IPI17474147  
GO:0008017microtubule binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0000226microtubule cytoskeleton organization-IBA21873635  
GO:0000226microtubule cytoskeleton organization-ISS-  
GO:0007052mitotic spindle organization-IMP21822276  
GO:0031175neuron projection development-IBA21873635  
GO:0051012microtubule sliding-IMP21822276  
GO:0051294establishment of spindle orientation-IGI21822276  
GO:0051294establishment of spindle orientation-IMP21822276  
GO:0051301cell division-IMP21822276  
GO:1902856negative regulation of non-motile cilium assembly-IMP23572511  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-IDA-  
GO:0005874microtubule-IEA-  
GO:0005875microtubule associated complex-TAS1905296  
GO:0005886plasma membrane-IDA-  
GO:0005930axoneme-IDA23572511  
GO:0014069postsynaptic density-IEA-  
GO:0015630microtubule cytoskeleton-IDA-  
GO:0030424axon-ISS-  
GO:0043005neuron projection-IBA21873635  
GO:0072686mitotic spindle-IDA21822276  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25519413Detecting longitudinal effects of haplotypes and smoking on hypertension using B-splines and Bayesian LASSO. (2014)Xia SBMC Proc
28322866Decreased anxiety, voluntary ethanol intake and ethanol-induced CPP acquisition following activation of the metabotropic glutamate receptor 8 "mGluR8". (2017 Apr)Bahi APharmacol Biochem Behav
9134211Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. (1997 Mar)Fundytus MEBr J Pharmacol